Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9591142 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2APOLBRAB9ANPC1 | |
| SCHEMBL11889494 | 0.90 | AR (0.53) | SMN1; SMN2KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL10030181 | 0.87 | L3MBTL1 (0.55) | SMN1; SMN2KMT2ARAB9AALDH1A1GAA | |
| SCHEMBL23094343 | 0.85 | LMNA (0.50) | SMN1; SMN2KMT2APOLBNPC1ALDH1A1 | |
| SCHEMBL10656932 | 0.85 | AR (0.50) | SMN1; SMN2KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL14962791 | 0.84 | KDM4E (0.50) | SMN1; SMN2KMT2APOLBRAB9ANPC1 | |
| SCHEMBL12515792 | 0.84 | AR (0.49) | SMN1; SMN2KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL24468248 | 0.84 | KDM4E (0.53) | SMN1; SMN2KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL12618074 | 0.84 | POLB (0.56) | SMN1; SMN2KMT2APOLBRAB9ANPC1 | |
| SCHEMBL26113771 | 0.84 | KDM4E (0.62) | SMN1; SMN2KMT2APOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543455-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | Enalare Therapeutics Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4504206-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250031718-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | SOVIDA SOLUTIONS LTD (GB) | 2025-01-30 | — | — | US | disclosed |
| US-12150461-B2 | Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof | Sovida Solutions Ltd. (GB) | 2024-11-26 | — | — | US | disclosed |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | ENALARE THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118829433-A | Respiratory stimulant parenteral formulations | 依那拉治疗股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4426308-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | Enalare Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118488840-A | Methods of treating respiratory depression modulated by non-opioid agents | 依那拉治疗股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023081185-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4121164-A1 | MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT | Tauriga Sciences Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115551592-A | Pharmaceutical cannabinoid compositions, methods of manufacture, and methods of treatment | 陶里加科学股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022235771-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234336-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-20220354879-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2022-11-10 | — | — | US | disclosed |
| WO-2022197581-A1 | NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT | TAURIGA SCIENCES INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220296561-A1 | NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT | TAURIGA SCIENCES INC (US) | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | OPRK1, OPRM1, OPRD1 | SMN1; SMN2 726/4885KMT2A 1896/4885POLB 1607/4885 |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | SMN1; SMN2 726/4885KMT2A 1896/4885POLB 1607/4885 |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | SMN1; SMN2 726/4885KMT2A 1896/4885POLB 1607/4885 |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ADRA2C, ADRA1B, CHRM3 | SMN1; SMN2 171/4885KMT2A 1852/4885POLB 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.